Abcam, ab250942, Anti-ACF1 / BAZ1A antibody [EPR15826] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ACF1 / BAZ1A antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR15826,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:ICC/IF, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250942 is the carrier-free version of
ab187670
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ACF1 also known as BAZ1A is a protein involved in DNA regulation. It is part of the ATP-utilizing chromatin assembly and remodeling factor (ACF) complex. This protein with a molecular mass of around 216 kDa is present mostly in the nucleus. ACF1 shows expression in various tissues including the brain and liver where it operates in regulating chromatin structure and gene accessibility.
Biological function summary
ACF1/BAZ1A is integral to chromatin remodeling which affects how DNA is packaged and accessed by other cellular machinery. It forms part of the ACF complex alongside the ISWI ATPase subunit heavily impacting nucleosome spacing and accessibility. ACF1/BAZ1A assists in nucleosome assembly and the establishment of regular chromatin structures important for gene expression regulation DNA replication and repair processes.
Pathways
ACF1/BAZ1A plays essential roles in pathways related to DNA repair and transcription regulation. In the DNA damage response pathway ACF1/BAZ1A works alongside other proteins like ISWI to ensure proper chromatin architecture facilitating DNA synthesis and repair mechanisms. It also contributes to transcription regulation by altering chromatin structure to allow transcription factors and RNA polymerase II access to DNA.
ACF1/BAZ1A associates with conditions involving genomic instability and cancer. Its role in chromatin remodeling makes it relevant in cancer where faulty chromatin regulation can lead to unchecked cell proliferation. ACF1/BAZ1A has connections with p53 a protein significant in the cellular response to DNA damage further implicating its importance in maintaining genomic integrity. Understanding this protein's role could aid therapeutic strategies targeting chromatin dynamics in these diseases.